Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

VMS and Menopause Atopic Dermatitis Provider Toolkit Adult Immunization Provider Toolkit Dermatology Hot Topics

Leon Kircik, MD

home / authors / leon-kircik-md

Articles

Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD

Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD

Leon Kircik, MD ;Grace Halsey

RAD 2025: Renowned AD investigator Kircik provides the history behind the class-wide black box warning, highlights JAK inhibitor efficacy, and toplines exciting AD research.

Editorial Board

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.